Aiolos launched in October 2023 with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with additional investment from RA Capital Management.

The company will advance its lead drug candidate, AIO-001, into a Phase II trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.